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Background: Fenestrated endovascular aneurysm repair (FEVAR) is increasingly being used for juxtare-
nal aortic aneurysms. The aim of this study was to review long-term results and assess the importance of
changing stent-graft design on outcomes.
Methods: This was a retrospective review of all patients who underwent FEVAR within a single unit
over 12 years (February 2003 to December 2015). Kaplan–Meier analysis of survival, and freedom from
target vessel loss, aneurysm expansion, graft-related endoleak and secondary intervention was performed.
Comparison between outcomes of less complex grafts (fewer than 3 fenestrations) and more complex
grafts (3 or 4 fenestrations) was undertaken.
Results: Some 173 patients underwent FEVAR; median age was 76 (i.q.r. 70–79) years and 90⋅2 per cent
were men. Median aneurysm diameter was 63 (59–71) mm and median follow-up was 34 (16–50) months.
The adjusted primary technical operative success rate was 95⋅4 per cent. The in-hospital mortality rate
was 5⋅2 per cent; there was no known aneurysm-related death during follow-up. Median survival was
7⋅1 (95 per cent c.i. 5⋅2 to 8⋅1) years and overall survival was 60⋅1 per cent (104 of 173). There was a
trend towards an increasing number of fenestrations in the graft design over time. In-hospital mortality
appeared higher when more complex stent-grafts were used (8 versus 2 per cent for stent-grafts with
3–4 versus fewer than 3 fenestrations; P =0⋅059). Graft-related endoleaks were more common following
deployment of stent-grafts with three or four fenestrations (12 of 90 versus 6 of 83; P <0⋅001).
Conclusion: Fenestrated endovascular aneurysm repair for juxtarenal aneurysm is associated with few
aneurysm-related deaths in the long term. Significant numbers of secondary interventions are required,
but the majority of these can be performed using an endovascular approach.
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Introduction
The treatment of a juxtarenal aortic aneurysm by fenes-
trated endovascular aneurysm repair (FEVAR) was first
reported in 19991. FEVAR has become the commonest
treatment for juxtarenal aneurysms, with 263 procedures
reported in the UK in 20152. The UK-wide BSET GLOB-
ALSTAR (British Society for Endovascular Therapy:
Global Collaborators on Advanced Stent-Graft Tech-
niques for Aneurysm Repair) registry has established the
safety and efficacy of the technique by reporting short-
and medium-term outcomes of initial procedures under-
taken during 2003–20093. Reports of long-term outcomes
are sparse4 and as such long-term durability remains
uncertain.
FEVAR stent-graft design has changed over the past
decade, with a trend towards a more proximal seal zone,
necessitating more fenestrations or scallops to maintain
visceral perfusion. Although this may allow the treatment
of more complex aneurysms, it is perceived by the authors
that it is also being applied to juxtarenal aneurysms that
were previously treated using less complex grafts.
BSET GLOBALSTAR3 recorded an increased inpatient
mortality rate of 9⋅4 per cent after use of stent-grafts that
incorporated the coeliac trunk compared with 2⋅8 per
cent for those that did not. As such, the widely reported
short- and medium-term outcomes of early case series may
not reflect the outcomes of stent-grafts used in modern
practice.
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The aim of this study was to assess the overall long-term
outcomes following FEVAR for the treatment of juxtarenal
aortic aneurysms in a single centre, and to observe the effect
of changes in stent-graft design.
Methods
Data for all patients undergoing FEVAR for juxtarenal
aortic aneurysm in the Liverpool Vascular and Endovas-
cular Service between February 2003 and December 2015
were included in the analysis. Patients who underwent
an endovascular repair involving branched components
or fenestrations with a proximal thoracic extension were
excluded as these procedures were deemed to represent
thoracoabdominal aneurysm repairs. Information was
obtained by retrospective review of institutional data
including patient demographics, aneurysm characteristics,
operative details and postoperative surveillance. Confir-
mation of mortality data were obtained from National
Health Service (NHS) institutional information. Cause of
death was obtained from patient’s general practitioners or
death certificates.
A target vessel was defined according to a previously pub-
lished report5 on FEVAR, as ‘a vessel potentially covered
by the stent-graft fabric if not for a deliberate mecha-
nism of preservation, when the stent-graft is deployed as
intended’. A fenestration was defined as a ‘deliberate defect
either circular or elliptical’ and a scallop as a ‘U-shaped
gap in the proximal fabric of the graft’5.
Two subgroups were created, divided by the median
number of fenestrations in implanted stent-grafts. This
created a group of grafts with no, one or two (fewer than
3) fenestrations and a group with three or four fenestra-
tions. Clinically, this relates to patients who would nor-
mally undergo stenting of a mesenteric vessel (3 or 4
fenestrations) or not (fewer than 3).
The primary endpoint was overall survival. Secondary
endpoints were freedom from target vessel loss, aneurysm
growth, graft-related (type I or III) endoleak and secondary
intervention. Definitions of success, complications and
other events associated with endovascular repair were in
accordance with accepted reporting standards6,7. The pri-
mary outcome was calculated using NHS data and as such
patients were censored only at the point of data collection.
If the patient was known to be alive and still on the surveil-
lance programme, their last follow-up surveillance imaging
was taken as the last point of data collection for secondary
outcomes. If the patient was followed up elsewhere and
hence not in the local programme, their last point of
imaging was taken as the last follow-up time point for
secondary outcomes. All planned secondary interventions
Table 1 Preoperative data for patients undergoing fenestrated
endovascular repair in a single UK centre
No. of patients* (n= 173)
Age (years)† 76 (70–79)
Sex ratio (M : F) 156 : 17






Not known 82 (47⋅4)
Hypertension
Known 110 (63⋅6)





Previous aortic surgery‡ n=103
Yes 9 (8⋅7)
No 94 (91⋅3)





Haemoglobin (g/l)† 138 (127–147)
Systolic BP (mmHg)† 135 (122–146)
Preoperative ECG n=162
Normal 76 (46⋅9)
Atrial fibrillation 12 (7⋅4)
Other abnormality 74 (45⋅7)
Left ventricular ejection fraction (%)† 60 (51–64)
FEV1 (litres)† 2⋅1 (1⋅6–2⋅6)
Creatine clearance (ml/min)† 55 (43–65)






Aneurysm diameter (mm)† 63 (59–71)
*With percentages in parentheses unless indicated otherwise; †values are
median (i.q.r.). ‡Fenestrated endovascular repair to treat complication.
FEV1, forced expiratory volume in 1 s.
were undertaken within the primary institution; unplanned
interventions were detected on the next imaging or
recorded if correspondence was received. This arrange-
ment was limited to the author’s early experience as all
patients now attend this institution for follow-up imaging.
Assessment of renal function
Preoperative renal function was calculated as creati-
nine clearance, using the Cockcroft–Gault formula. All
calculations were based on ideal bodyweight calculated
from the patient’s sex and preoperative height.
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Table 2 Fenestrated endovascular aneurysm repair stent-graft configuration in a single UK centre
No. of target vessels No. of patients Coeliac axis SMA RRA LRA
4 (44⋅5) 30 Fenestration Fenestration Fenestration Fenestration
47 Scallop Fenestration Fenestration Fenestration
3 (46⋅8) 11 Fenestration Fenestration Fenestration
62 Scallop Fenestration Fenestration
4 Fenestration Fenestration Fenestration to RRA or LRA renal
3 Scallop Fenestration Fenestration to RRA or LRA renal
1 Scallop Scallop Fenestration





1 (5⋅2) 9 Scallop to RRA or LRA renal
Values in parentheses are percentage of patients. *Patient with end-stage renal failure on dialysis. SMA, superior mesenteric artery; RRA, right renal
artery; LRA, left renal artery.
Follow-up protocol
A standardized post-FEVAR surveillance protocol was
developed including plain abdominal X-ray before dis-
charge, duplex ultrasonography and single arterial-phase
CT angiography (CTA) after 1 month, with clinical review
6 weeks after surgery. Abdominal X-ray, duplex ultra-
sonography and CTA were repeated after 6 months, then
annually. If complications or potential problems were iden-
tified, patients were discussed at a multidisciplinary team
meeting. Further imaging in the form of triple-phase CTA
or contrast-enhanced ultrasonography was performed
if deemed appropriate, and secondary intervention was
undertaken if indicated clinically. Loss of a target vessel
was defined as complete occlusion of the target vessel
main stem.
Statistical analysis
Continuous data are presented as median (i.q.r.). Overall
survival, target vessel loss, graft-related endoleak and
secondary intervention were all subject to Kaplan–Meier
analysis and log rank comparison using RStudio® version
0.99 (RStudio, Boston, Massachussetts, USA). Median
follow-up was determined by means of the reverse
Kaplan–Meier technique. All other statistical analysis
was done using SPSS® version 22 (IBM, Armonk, New
York, USA).
Results
During the 12-year study interval, some 209 patients
underwent a branched and/or fenestrated procedure in
the authors’ institution, of whom 174 were eligible for
inclusion in this analysis. One patient in whom the oper-
ation failed was excluded from the analysis. The device
could not be introduced past a stenotic aortic bifurca-
tion and the procedure was abandoned. This patient
remained alive 34 months after the failed operation. Base-
line data for the remaining 173 patients are summarized in
Table 1.
Stent-graft configuration
All patients were treated with fenestrated stent-grafts
produced by a single manufacturer (Cook Medical, Bloom-
ington, Indiana, USA). The stent-graft configuration was
recorded for all patients (Table 2). The most common
stent-graft and target vessel configuration was a scallop for
the superior mesenteric artery (SMA) and a fenestration
for each of the renal arteries (62 patients, 35⋅8 per
cent). Over the duration of the study there was a trend
towards an increasing number of target vessels (Fig. 1).
Comparison of 2004 and 2015 showed a significant dif-
ference in the number of target vessels (median 3 versus
4; Z-score= 4⋅64, P < 0⋅001, Mann–Whitney U test).
Aneurysm and stent-graft D1 (neck) diameter did not
display any trend over time and are presented as surro-
gate markers of aneurysm morphology (Figs S1 and S2,
supporting information).
Operative data
The fenestrated device was introduced successfully in 173
patients. Two target vessels (0⋅3 per cent) were lost dur-
ing surgery, in separate patients; both were renal arteries.
There were 35 patients with a graft-related endoleak (type
I or III) on completion of the procedure. The primary tech-
nical success rate was 79⋅2 per cent (137 of 173 patients).
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1020–1027
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Fig. 1 Percentage of stent-grafts with each number of target vessels by calendar year
Twenty-nine of the 35 graft-related endoleaks identified
on completion angiography had resolved without interven-
tion by the 1-month surveillance imaging. This gave an
adjusted primary technical success rate of 95⋅4 per cent
(165 patients).
The median duration of operation was significantly
shorter for stent-grafts implanted with fewer than three
fenestrations than those with three or four fenestrations
(285 (95 per cent c.i. 240 to 330) versus 360 (300 to
485) min; P < 0⋅001). Some 29 unplanned intraoperative
manoeuvres were required to ensure adequate aneurysm
treatment in 29 patients (Table 3).
Target vessels
There was a total of 572 target vessels. Of these, 126 (22⋅0
per cent) were preserved with a scallop and 446 (78⋅0 per
cent) with a fenestration. It was routine practice to place a
stent in all fenestrations; however, this was not possible in
four instances.
Of the 126 vessels preserved with a scallop, ten (7⋅9 per
cent) required a stent (9 renal arteries and 1 SMA). In total
452 vessels were stented. The stent type was known in 419
procedures. Bare metal stents were used in 80 target vessels
(53 Palmaz® Genesis®, Cordis, Miami Lakes, Florida,
USA; 27 others). Covered stents were used in 339 target
vessels (325 Advanta™, Atrium Medical, Hudson, New
Hampshire, USA; 14 others).




Extra target vessel stent Maldeployment/endoleak 5
Target vessel dissection 2
Target vessel perforation 2
Unknown 2
Unplanned upper limb access Failure to cannulate target
vessel
2
Limb extension/Wallstent™ Kink/flow limitation 7
Type Ib endoleak 3
Iliac rupture 2
Insufficient limb overlap 1
Unplanned femorofemoral
bypass
Insufficient limb flow 2
Unplanned iliofemoral bypass Iliac rupture 1
Wallstent™ (Boston Scientific, Marlborough, Massachusetts, USA).
Perioperative mortality and complications
A total of nine patients (5⋅2 per cent) died during the
primary hospital admission. The cause of death was
embolic ischaemia of abdominal viscera (3), myocardial
infarction (2), multiple organ failure (2), retroperi-
toneal bleed from a target vessel (1) and aspiration
pneumonia (1). Of those who died from abdominal
viscera ischaemia, one patient had a stent-graft with
four fenestrations, and the remaining two patients had
stent-grafts with three fenestrations and a scallop for the
coeliac axis.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1020–1027
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Table 4 Inpatient complications prolonging hospital stay and surgical interventions
Complication No. of patients Surgical interventions




Acute respiratory distress syndrome 1
Neurological Acute delirium 3
Transient paraplegia 2 Spinal drainage
Urinary Acute kidney injury 7 Temporary dialysis 3
Acute retention 2
Urinary tract infection 2
Renal hypertension from ischaemia 1
Gastrointestinal Bleeding 1 Upper gastrointestinal endoscopy
Ischaemia 4 Gastrectomy and splenectomy 1*
Left hemicolectomy 1†
Hartmann’s procedure 1*
Acute SMA stent angioplasty 1†
Prolonged ileus 2
Access complications Groin bleeding 3 Surgical exploration
Bypass graft occlusion 1 Redo iliofemoral graft

































Time after surgery (years)
No. at risk 173 139 107 81 65 51
3 4 5
50
Fig. 2 Freedom from mortality (all-cause) following fenestrated
endovascular aneurysm repair in a single UK centre
Mortality rates according to stent-graft complexity were
similar: 2 of 83 patients (2 per cent) who received devices
with fewer than three fenestrations died in hospital,
compared with seven of 90 (8 per cent) whose stent-grafts
had three or four fenestrations (P = 0⋅059).
In the postoperative period, 47 patients (27⋅2 per cent)
had 53 primary complications which prolonged hospi-
tal stay (Table 4). Both patients with transient paraplegia
underwent implantation of four-fenestration stent-grafts
and had patent lumbar arteries excluded by the stent-graft.













































Fig. 3 Freedom from type I or III endoleak following fenestrated
endovascular aneurysm repair in a single UK centre in relation to
number of fenestrations in stent-graft. P < 0⋅001 (log rank test)
iliac artery. Both had spinal drains inserted on discov-
ery of their symptoms and subsequently recovered. Eleven
patients required a surgical intervention. These are distinct
from the five patients who had secondary interventions
to maintain FEVAR efficacy before discharge, reported in
secondary interventions.
Median length of hospital stay was 7 (5–11) days (167
patients), and did not differ between stent-graft complexity
groups (P = 0⋅476).
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1020–1027
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Fig. 4 Freedom from secondary intervention following
fenestrated endovascular aneurysm repair in a single UK centre
in relation to number of fenestrations in stent-graft. P = 0⋅508
(log rank test)
Renal function
Three patients (1⋅7 per cent) required temporary
dialysis, but none needed new permanent dialysis
(Table 4). Forty-seven (27⋅8 per cent) of 169 patients
with available data suffered from acute kidney injury
(more than 1⋅5-fold increase in serum creatinine). No
patient required new permanent dialysis in recorded
follow-up.
Follow-up
Median follow-up was 34 (i.q.r. 16–50) months. All-cause
survival was 59⋅4 per cent (95 per cent c.i. 50⋅7 to
69⋅5) years at 5 years. Overall median survival was 7⋅1
(95 per cent c.i. 5⋅2 to 8⋅1) years. Sixty-nine patients
died during follow-up (Fig. 2). There were no reported
aneurysm-related deaths. Freedom from loss of any tar-
get vessel and secondary intervention was 90⋅1 (82⋅9 to
97⋅9) and 62⋅8 (51⋅7 to 76⋅3 per cent) respectively at
5 years. Ten-year results for each outcome are presented in
Figs S3–S7 (supporting information).
Rates of graft-related endoleak were higher in patients
who received stent-grafts with three or four fenestrations
versus fewer than three fenestrations (12 of 90 (13 per cent)
versus 6 of 83 (7 per cent) respectively; P < 0⋅001) (Fig. 3).
There were no significant differences between groups in
secondary interventions (20 of 90 (22 per cent) versus 14
of 83 (17 per cent); P= 0⋅508) (Fig. 4), aneurysm growth
(18 of 90 (20 per cent) versus 19 of 83 (23 per cent);
P = 0⋅160) (Fig. S8, supporting information) and freedom
from loss of a target vessel (84 of 90 (93 per cent) versus
78 of 83 (94 per cent); P= 0⋅272) (Fig. S9, supporting
information). Survival was similar in the groups with more
and less complex stent-grafts (72 of 90 (80 per cent) versus
32 of 83 (39 per cent); P= 0⋅264) (Fig. S10, supporting
information),
Thirty-four patients required a secondary intervention
during follow-up. The first secondary intervention was
endovascular in 30 patients and four required open surgery.
Most interventions were on target vessel stents (19) or
limbs (8), and were indicated by endoleaks or stenosis. Six
patients required more than one secondary intervention,
which resulted in a total endovascular rate of 82 per cent
(36 of 44) for all secondary interventions.
Discussion
FEVAR is an effective and safe method for treating
aneurysms not suitable for standard endovascular repair,
in the short to medium term. These observations were
confirmed in the present cohort. The inpatient mortal-
ity rate of 5⋅2 per cent in this series is higher than the
GLOBALSTAR rate of 4⋅1 per cent4. Meta-analyses have
reported a pooled mortality rate of 2 per cent8 and 2⋅5
per cent9 within 30 days, lower than the 30-day mortality
rate of 3⋅4 per cent the present cohort. One possible
explanation for this is the use of a higher proportion of
devices with three or four fenestrations in the present
series.
One of the difficulties associated with reporting of out-
comes of patients with aortic aneurysms is the lack of
standard reporting criteria. No clear guidance exists to
define juxtarenal aneurysm. A number of terms are used in
everyday clinical practice, including juxtarenal, pararenal
and suprarenal aneurysm. It would help greatly in com-
paring the outcomes of different interventions if these
were defined consistently. The present series demonstrated
a trend towards higher hospital mortality after deploy-
ment of more complex stent-grafts (3 or 4 fenestrations)
and this may simply be a reflection of the more com-
plex aortic morphology. Over time there has been an
increasing use of more complex stent-grafts to deal with
juxtarenal aneurysms in the author’s centre, and anecdotally
among other centres. The advantage of using more com-
plex stent-grafts is that the sealing zone is generally pushed
higher in the aorta, thus offering a potentially more durable
proximal seal in relatively healthy aorta. More complex
stent-grafts may come at a cost of increasing operating
time and rates of graft-related endoleak because of the
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1020–1027
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larger number of fenestrations. The lack of difference in
rates of aneurysm expansion, secondary interventions and
all-cause mortality between stent-grafts of varying com-
plexity may simply be due to the relatively small numbers of
patients.
The primary technical success rate in this series of 79⋅2
per cent on completion angiography was relatively lower
than in other contemporary series (96⋅8 per cent)8. The
authors do not routinely balloon mould through the fen-
estrated segment in order to preserve target vessel stent
alignment. The majority of these endoleaks (29 of 35)
had resolved without intervention by the 1-month surveil-
lance imaging. An adjusted primary technical success rate
of 95⋅4 per cent (165 of 173) is more representative of
data from other centres, which may have different intra-
operative reporting practices. Alternatively, heterogene-
ity in intraoperative heparinization regimens and attitudes
to time for stent-graft conformation to occur, without
balloon moulding, may account for the discrepancy in pri-
mary endoleak rates9.
Freedom from target vessel loss was 90⋅1 per cent at
5 years in this series. The attrition rate of target vessels
is therefore surprisingly low even in the long term, and
none of the target vessels that occluded resulted in seri-
ous clinical consequences for any patient. This is within the
context of a robust surveillance programme which identi-
fies and can act upon threats to target vessel patency. These
results are in line with those of another long-term study4
with median follow-up of 67 months, confirming that tar-
get vessel loss does not appear to be a significant problem
with fenestrated technology.
The present data appear to confirm the benefit of fenes-
trated EVAR technology for juxtarenal aneurysm repair in
the long term. There were no aneurysm-related deaths in
longer-term follow-up and the overall survival was encour-
aging for a population of patients with aortic aneurysm.
A significant number of complications were identified
during postoperative surveillance; however, interventions
to deal with these seemed effective. Secondary inter-
ventions performed after discharge were, in the main,
endovascular procedures. The frequency of secondary
intervention (37⋅2 per cent over 5 years) confirms the need
for continued stent-graft surveillance.
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Snapshot quiz 17/7
Answer: This 81-year-old woman has locally advanced transverse colonic cancer invading into the anterior abdominal wall.
The sign depicted in b
as ‘pants button umbilicus’ before the term SMJN was coined by Hamilton Bailey1. SMJN is a cancer deposit in the
umbilicus, and the commonest primary neoplasm is of gastrointestinal tract (35–65 per cent), followed by gynaecological
(12–35 per cent) origin. A SMJN sign suggests advanced metastatic disease and has a poor prognosis.
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